Compare Hilton Hotels Corporation Common Stock (HLT) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hilton Hotels Corporation Common Stock vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Hilton Hotels Corporation Common Stock trades at $329.58 (market cap $73.82B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M). The key difference: Hilton Hotels Corporation Common Stock is far larger — about 75.5× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Hilton Hotels Corporation Common Stock pays a 0.18% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hilton Hotels Corporation Common Stock for 139 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| HLT | MRVI | |
|---|---|---|
Market Cap | $73.82B | $977.37M |
Volume | 1,126,885 | 2,742,564 |
Sector | Consumer Cyclical | Health |
52-Week High | $350.22 | $9.00 |
52-Week Low | $256.96 | $2.83 |
Typical Hold Time | 139 Days | 0 Days |
Enterprise Value | $86.84B | $1.08B |
Dividend Yield | 0.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hilton Worldwide (HLT) trades at $329.59, up 0.63% with strong technical momentum and bullish moving average signals. The company demonstrates solid fundamentals with consistent revenue growth from $8.8B in 2022 to $12.0B in 2025, maintaining double-digit net income margins. Recent earnings beats and positive analyst sentiment (57% buy ratings) support the bullish case, though elevated valuation metrics (P/E 48.4) and negative shareholder equity warrant caution.
Outlook remains positive with Q3 2026 earnings anticipated on October 27, 2026, and consensus price target of $350 offering 6% upside. Key risks include high debt levels (debt-to-asset ratio 73.88% in 2025) and potential travel sector volatility. Institutional accumulation and strong cash flow generation provide fundamental support for long-term investors despite near-term overbought technical conditions.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Hilton Hotels Corporation Common Stock
Hilton Worldwide Holdings operates 1,074,791 rooms across its 18 brands addressing the midscale through luxury segments as of Dec. 31, 2021. Hampton and Hilton are the two largest brands by total room count at 28% and 21%, respectively, as of Dec. 31, 2021. Recent brands launched over the last few years include Home2, Curio, Canopy, Tru, and Tempo. Managed and franchised represent the vast majority of adjusted EBITDA, predominantly from the Americas regions.
Read more on HLT →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
